IPP Bureau
FDA approves UCB’s Kygevvi for rare genetic mitochondrial disease TK2 deficiency
By IPP Bureau - November 06, 2025
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Bayer's finerenone approved in India for heart failure
By IPP Bureau - November 06, 2025
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Teva reports 11th consecutive quarter of growth
By IPP Bureau - November 06, 2025
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
IPP organises webinar on "Transforming Formulation R&D: Data, Digitalization and Beyond" on November 6, 2025
By IPP Bureau - November 05, 2025
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Glenmark Pharmaceuticals USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq Single-Dose Vial
By IPP Bureau - November 05, 2025
Glenmark will begin distribution in November 2025
Zydus receives FDA’s tentative approval for Budesonide delayedrelease capsules, 4 mg
By IPP Bureau - November 05, 2025
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
Henkel launches Packaging RecycLab in China
By IPP Bureau - November 05, 2025
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
Kulzer reshapes global strategy to drive growth in EMEA and Americas
By IPP Bureau - November 04, 2025
Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany
Roche’s Gazyva shows breakthrough efficacy in phase III lupus study
By IPP Bureau - November 04, 2025
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Effective corrosion management demands a holistic approach: Experts
By IPP Bureau - November 04, 2025
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Akums Drugs gets 20- year patent for "Dual Release Gastro-Resistant Composition"
By IPP Bureau - November 04, 2025
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Lilly to build $3 billion oral medicine facility in Netherlands
By IPP Bureau - November 04, 2025
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
By IPP Bureau - November 04, 2025
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Kimberly-Clark to acquire Kenvue in $48.7 billion mega deal
By IPP Bureau - November 04, 2025
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
.jpg "Cipla to acquire Inzpera Healthsciences for Rs. 110.65 Cr")
Cipla to acquire Inzpera Healthsciences for Rs. 110.65 Cr
By IPP Bureau - November 04, 2025
The transaction is expected to be completed within one month from the signing of the definitive agreements.
